Unandup, LLC
St. Louis, MO
- UEI
- KS8GMBKHNKV3
- CAGE
- 80L26
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Partnership or Limited Liability Partnership
- SAM.gov registration date
- Physical address
- 4220 Duncan Ave #201, St. Louis, MO 63110, USA
- Website
- unandup.com
- Founded
- 2018
- Employees
- 1-10
- Estimated annual revenue
- $1M-$10M
- Industry
-
- Health Care
- Health Care Equipment & Services
- Health Care Providers & Services
- SIC code
- 38 Instruments & Related Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Grant awards
Latest 5 listed here. See the rest on GovTribe.
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Mtti | West Chester, PA | 325413 In-Vitro Diagnostic Substance Manufacturing |
| Coridea, LLC | New York, NY | 541690 Other Scientific and Technical Consulting Services |
| Aneuvas Technologies Inc. | Flagstaff, AZ | — |
| Minnesota Healthsolutions Corporation | Minneapolis, MN | 541330 Engineering Services |
| Corvion, Inc. | Webster, TX | 334510 Electromedical and Electrotherapeutic Apparatus Manufacturing |
About the company
Unandup, LLC, a for-profit medical device technology company based in St. Louis, Missouri, operates as a prime recipient of federal research grants focused on magnetic and nanoparticle-based interventional medical platforms. The vendor holds no federal contracts; its entire footprint consists of Small Business Innovation Research and related grant awards from the National Institutes of Health across four distinct customer agencies.
Unandup's capability portfolio centers on proof-of-concept and early-stage development of magnetic particle delivery systems for minimally invasive cardiovascular and neurological interventions. Recent representative grant work includes a $405,753 Phase I Small Business Innovation Research award from the National Cancer Institute (Cancer Treatment Research program, CFDA 93.395) for magnetomotive embolization technology targeting hepatocellular carcinoma treatment, running through August 2027; a $2.4 million National Heart, Lung, and Blood Institute grant awarded April 2025 for magnetic rotational atherectomy platform development addressing coronary lesion debulking, completing March 2027; and two National Institute of Neurological Disorders and Stroke grants for nanoparticle-based thrombolysis platforms — one Phase I Commercialization Readiness Pilot awarded March 2025 and one Phase II award from July 2023 running through June 2027 — designed to accelerate clot-dissolving agent delivery in acute ischemic stroke.
Customer concentration is 100% National Institutes of Health. The National Heart, Lung, and Blood Institute accounts for five awards; the National Institute of Neurological Disorders and Stroke accounts for four; the National Cancer Institute accounts for three; and the National Institute for Minority Health and Health Disparities accounts for one award. The vendor's combined dollars obligated across all awards total $23.8 million. Activity has remained modest, averaging fewer than two awards annually over the past five years, with one award in 2026 and two in 2025. Five awards with ultimate completion dates in the next twenty-four months face renewal or recompete in that window.
Quick answers
Is Unandup, LLC registered in SAM.gov?
Yes. Unandup, LLC's SAM.gov registration is active through July 24, 2027.
What is Unandup, LLC's most recent federal award?
Unandup, LLC's most recent federal grant award is Improved magnetomotive embolization for hepatocellular carcinoma - cancer is the 2ND leading cause of death in the… (R43CA310649), from National Cancer Institute (NIH), on September 1, 2026.
On GovTribe
See Unandup, LLC's full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors